eCARTv5 Clinical Deterioration Suite (eCART) vs Sepsis ImmunoScore

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 78/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

eCARTv5 Clinical Deterioration Suite (eCART)

by AgileMD

Sepsis ImmunoScore

by Prenosis

AI Verdict

Tool A (eCARTv5) offers a broad AI-powered solution for predicting general clinical deterioration in hospitalized adult patients, guiding care with embedded pathways. Tool B (Sepsis ImmunoScore) is a specialized AI diagnostic specifically for sepsis, providing rapid risk assessment and prediction of adverse outcomes related to this condition. While both are FDA-cleared SaMDs integrating with EHRs to improve patient outcomes through risk prediction, their primary difference lies in eCARTv5's general scope versus Sepsis ImmunoScore's targeted focus on sepsis.

Choose eCARTv5 Clinical Deterioration Suite (eCART) if…

Choose eCARTv5 if your primary goal is comprehensive, continuous monitoring for general clinical deterioration across your entire adult hospitalized patient population. This tool is ideal for proactively identifying patients at risk of death or ICU transfer, providing early warnings and guiding care through embedded clinical pathways to improve overall patient safety and outcomes.

View eCARTv5 Clinical Deterioration Suite (eCART) →

Choose Sepsis ImmunoScore if…

Choose Sepsis ImmunoScore if your critical need is rapid and precise diagnosis and risk stratification specifically for sepsis. This FDA-authorized AI diagnostic excels at leveraging specific biomarkers and clinical data to predict sepsis-related adverse outcomes within 24 hours, enabling clinicians to make faster, more targeted treatment decisions for this time-sensitive condition.

View Sepsis ImmunoScore →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	eCARTv5 Clinical Deterioration Suite (eCART)	Sepsis ImmunoScore
Pricing	Contact vendor for tailored quote.	Enterprise subscription model
Deployment	Cloud-based SaaS, integrated directly into Electronic Health Record (EHR) systems.	Integrated into hospital EHR/EMR systems
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Sepsis ImmunoScore

Tool B, Sepsis ImmunoScore, explicitly highlights an 'intuitive display that explains how parameters contribute to the score (transparency)'. This transparency is crucial for building clinician trust and understanding in AI-driven recommendations. While Tool A, eCARTv5, aims to minimize false alarms and clinician workload, Tool B's focus on demystifying AI and explaining its rationale provides a stronger foundation for user adoption and confidence.

Clinical Value

Sepsis ImmunoScore

Tool B, Sepsis ImmunoScore, is distinguished as the 'first FDA-authorized AI diagnostic for sepsis'. This specific authorization for a critical and time-sensitive condition like sepsis signifies a high level of validated clinical utility and impact. While Tool A, eCARTv5, offers a broader prediction of general clinical deterioration, Tool B's groundbreaking status in a specific, high-stakes area gives it a notable edge in demonstrating focused clinical value.

Pricing & Value

Tie

Both tools employ an enterprise subscription model with non-public pricing, requiring prospective customers to contact the vendor for a tailored quote. Neither provides sufficient public information to compare their pricing structures or assess their value proposition directly. Therefore, it is not possible to distinguish between them on this dimension.

Enterprise Readiness

Sepsis ImmunoScore

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, BAA, and EHR integration. However, Tool B, Sepsis ImmunoScore, benefits from an 'exclusive distribution partnership with Roche Diagnostics'. This partnership suggests a potentially more robust and established channel for enterprise-level sales, deployment, and ongoing support, which can be a significant advantage for large healthcare systems.

Innovation

Sepsis ImmunoScore

While both tools leverage AI/ML for critical clinical decision support, Tool B, Sepsis ImmunoScore, stands out as the 'first FDA-authorized AI diagnostic for sepsis'. This specific regulatory milestone for a targeted, high-impact condition represents a unique and recognized innovation in the field of AI-driven diagnostics. Tool A's continuous assessment for general deterioration is innovative, but Tool B's 'first' status marks a distinct breakthrough.

Support & Docs

Tie

The provided structured facts for both tools do not include specific details regarding their support services or documentation. While general information about AgileMD's support (Email, Phone, Chat, FAQ, etc.) is available through web searches, a direct comparison of the quality or comprehensiveness of support and documentation between the two tools cannot be made with the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	eCARTv5 Clinical Deterioration Suite (eCART)	Sepsis ImmunoScore
Tool Name	eCARTv5 Clinical Deterioration Suite (u201ceCARTu201d)	Sepsis ImmunoScore
Company	AgileMD	Prenosis
Description	FDA-cleared, AI-powered Software as a Medical Device (SaMD) that integrates with EHRs to continuously assess and predict the risk of clinical deterioration (death or ICU transfer) in hospitalized adult patients, guiding care with embedded clinical pathways.	First FDA-authorized AI diagnostic for sepsis, providing rapid risk assessment and prediction of adverse outcomes. It analyzes 22 parameters from EHRs to generate a risk score and four risk categories, aiding clinicians in faster treatment decisions and improved patient outcomes.
Key Focus	Clinical deterioration (death or ICU transfer)	Sepsis diagnosis and prediction of adverse outcomes
Parameters Analyzed	Up to 97 variables	22 diverse parameters (biomarkers and clinical data)
Output	eCART score and risk designation, alerts hours before critical illness, embedded clinical pathways	Risk score and four discrete risk categories, prediction of deterioration (length of stay, in-hospital mortality, ICU admission, mechanical ventilation, vasopressor use) within 24 hours

Videos

Demos, reviews, and walkthroughs featuring eCARTv5 Clinical Deterioration Suite (eCART) and Sepsis ImmunoScore.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical focus of each tool?

eCARTv5 Clinical Deterioration Suite focuses on continuously assessing and predicting the risk of general clinical deterioration (death or ICU transfer) in hospitalized adult patients. Sepsis ImmunoScore, on the other hand, is specifically designed as the first FDA-authorized AI diagnostic for sepsis, providing rapid risk assessment and prediction of adverse outcomes in sepsis patients.

How do the tools differ in the type and number of data points they analyze from the EHR?

eCARTv5 integrates with EHRs to analyze up to 97 variables for continuous patient risk assessment. In contrast, Sepsis ImmunoScore leverages 22 diverse parameters, including biomarkers and clinical data, from EHRs to generate its risk score.

What kind of clinical guidance or output does each tool provide to aid decision-making?

eCARTv5 provides an eCART score, risk designation, and embedded clinical pathways for care guidance, functioning as an early warning system that alerts hours before critical illness. Sepsis ImmunoScore outputs a risk score and four discrete risk categories, and it features an intuitive display that explains how individual parameters contribute to the score, fostering transparency.

What specific patient outcomes do these tools predict?

eCARTv5 predicts the risk of clinical deterioration, specifically death or ICU transfer, in hospitalized adult patients. Sepsis ImmunoScore predicts the risk of deterioration within 24 hours, including length of stay, in-hospital mortality, ICU admission, mechanical ventilation, and vasopressor use, for sepsis patients.

How do these tools integrate into existing hospital workflows and EHR systems?

Both eCARTv5 and Sepsis ImmunoScore are designed for direct integration into hospital Electronic Health Record (EHR) or Electronic Medical Record (EMR) systems. eCARTv5 is a cloud-based SaaS solution, while Sepsis ImmunoScore is integrated into hospital EHR/EMR systems.

Does either tool offer transparency into how its risk scores are derived?

Sepsis ImmunoScore explicitly features an intuitive display that explains how each of the 22 patient parameters contributed to the final sepsis score, aiming to build clinician trust and partnership. The description for eCARTv5 mentions providing an eCART score and risk designation but does not explicitly detail this level of transparency in its score derivation.